Antimicrobial resistance (AMR) is one of the top global public health and development threats. According to a 2022 article published in the Lancet, it is estimated that bacterial AMR was directly responsible for 1.27 million global deaths in 2019 and contributed to 4.95 million deaths.

Antimicrobial resistance: a growing issue

The misuse and overuse of antimicrobials in humans, animals and plants are the main drivers in the development of drug-resistant pathogens.

Without effective tools for the prevention and adequate treatment of drug-resistant infections and improved access to existing and new quality-assured antimicrobials, the number of people for whom treatment is failing or who die of infections will increase. Medical procedures, such as routine surgery (including caesarean sections or hip replacements), cancer chemotherapy, and organ transplantation, will become more risky.

Why attend BioInfect?

The agenda at BioInfect will focus on the issues surrounding the increasing threat of AMR and how it can be addressed, including working towards an integrated, unifying approach that aims to achieve optimal and sustainable health outcomes; antimicrobial stewardship; increased investment and innovation in new treatments at all stages of the drug development pipeline and ensuring ROI in the development of new antimicrobials; and the use of strategic information to inform the AMR response.